Furthermore, the combination of anti-PI3K/AKT signaling agents with other conventional anti-tumor drugs may represent a new direction to overcome the intracellular escape mechanisms of conventional chemotherapies and increase chemosensitivity in patients with USC16[27,28]. The gene discussed is PIK3CA; the disease is neoplasm.